A nano-enzyme / deoxyribozyme synergistic anti-inflammatory complex targeting macrophages and application thereof in preparation of drugs for inflammatory diseases

By using a nanozyme/deoxyribonuclease synergistic anti-inflammatory complex, precise targeting and efficient anti-inflammatory effects are achieved at the site of inflammation, solving the problems of poor targeting and insufficient stability of existing anti-inflammatory drugs. This significantly improves the therapeutic effect and reduces side effects, making it suitable for the treatment of a variety of inflammatory diseases.

CN122828140APending Publication Date: 2026-09-29CHINA PHARM UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202611013985.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-07-08
Publication Date
2026-09-29

AI Technical Summary

Technical Problem

Existing anti-inflammatory drugs have poor targeting, significant systemic side effects, are prone to relapse, and have poor long-term tolerance. Single nanozymes cannot block inflammatory signaling pathways, and deoxyribonucleases have poor stability and lack efficient targeted delivery systems, making it difficult to achieve efficient, safe, and precise anti-inflammatory treatment.

Method used

A nanozyme/deoxyribozyme synergistic anti-inflammatory complex was developed. The nanozyme and deoxyribozyme were constructed through self-assembly. The nanozyme and deoxyribozyme were combined through charge adsorption. The L-arginine-modified polymer material was used to achieve targeted delivery to the site of inflammation. The nanozyme cleared ROS, and the deoxyribozyme silenced the inflammatory signaling pathway, thus achieving a dual anti-inflammatory effect.

Benefits of technology

It significantly improves the treatment effect of inflammatory diseases, reduces side effects, achieves precise targeting and efficient anti-inflammatory effects at the site of inflammation, regulates the intestinal flora structure, repairs the intestinal mucosal barrier, and provides multi-dimensional treatment for a variety of inflammatory diseases.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses a nano-enzyme / deoxyribozyme synergistic anti-inflammatory compound for treating inflammatory diseases, which comprises a nano-enzyme and a deoxyribozyme, and the nano-enzyme and the deoxyribozyme are combined into a nanoscale synergistic anti-inflammatory compound through self-assembly; the nano-enzyme is a metal-polyphenol nano-enzyme prepared from metal ions and polyphenols, and the metal-polyphenol nano-enzyme is prepared together with a targeting modification carrier. The application discloses a use of the nano-enzyme / deoxyribozyme synergistic anti-inflammatory compound in preparation of a medicine for treating inflammatory diseases. The compound combines ROS scavenging activity of the nano-enzyme with gene silencing function of the deoxyribozyme, constructs a double synergistic anti-inflammatory mechanism of "ROS scavenging-inflammation signal silencing", and can more comprehensively and efficiently inhibit inflammatory reactions and block inflammatory progress from multiple links, so that the treatment effect is obviously improved, as compared with single nano-enzyme (only capable of scavenging ROS) and single deoxyribozyme (only capable of silencing inflammatory genes).
Need to check novelty before this filing date? Find Prior Art